Regulatory
Motif Bio plc announces that formal notice was given by the Company to Nasdaq on November 25, 2019 of the intention to voluntarily delist the Company’s American Depository Shares and listed warrants from the Nasdaq Capital Market.
Promore Pharma AB has prepared a supplementary prospectus to the prospectus regarding the rights issue of approx.
Innovation Pharmaceuticals, a clinical stage pharmaceutical company, is pleased to inform shareholders the Company received notification from the Food and Drug Administration that a waiver has been granted eliminating the need to study Brilacidin, for the prevention of Severe Oral Mucositis in Head and Neck Cancer patients receiving chemoradiation, in pediatric populations.
Patent covers use of MANF in Glaucoma, Wolfram Syndrome and Retinitis Pigmentosa
Mitchell Hamline School of Law is pleased to announce the first annual Roy Snell Health Care Regulatory & Compliance Writing Competition.
Synergistic Therapeutics LLC has recently announced the issuance of a U.S. Patent for a Topical Analgesic Lotion that relieves pain.
Oxford Gene Technology, A Sysmex Group Company, is proud to announce that its new facility in Cambridge, UK, has achieved Medical Device Single Audit Program certification of its quality management system
Levo Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation for LV-101 for the treatment of Prader-Willi syndrome Levo is currently enrolling participants in its Phase 3 clinical study of intranasal carbetocin for the treatment of PWS.
It is the first BeiGene-discovered drug to be approved.
The advisory committee voted 14 to 2 that the benefits of the drug did not outweigh the risks to support approval. The FDA is not obligated to follow the recommendation, but typically do.
PRESS RELEASES